SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-015054
Filing Date
2021-11-08
Accepted
2021-11-08 16:30:58
Documents
54
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ruby-20210930x10q.htm   iXBRL 10-Q 2047350
2 EX-31.1 ruby-20210930xex31d1.htm EX-31.1 18875
3 EX-31.2 ruby-20210930xex31d2.htm EX-31.2 18795
4 EX-32.1 ruby-20210930xex32d1.htm EX-32.1 8130
5 EX-32.2 ruby-20210930xex32d2.htm EX-32.2 8111
  Complete submission text file 0001558370-21-015054.txt   5588899

Data Files

Seq Description Document Type Size
6 EX-101.SCH ruby-20210930.xsd EX-101.SCH 31783
7 EX-101.CAL ruby-20210930_cal.xml EX-101.CAL 41295
8 EX-101.DEF ruby-20210930_def.xml EX-101.DEF 89172
9 EX-101.LAB ruby-20210930_lab.xml EX-101.LAB 322563
10 EX-101.PRE ruby-20210930_pre.xml EX-101.PRE 217515
11 EXTRACTED XBRL INSTANCE DOCUMENT ruby-20210930x10q_htm.xml XML 714698
Mailing Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

IRS No.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38586 | Film No.: 211388421
SIC: 2836 Biological Products, (No Diagnostic Substances)